Molecular Partners has initiated a Phase 1/2a study for Radio-DARPin MP0712, with initial data expected in 2026. Data from the MP0712 compassionate care program will be presented at TWC 2026. A Phase 2 trial for MP0317 is now open, exploring its use in combination with standard-of-care for cholangiocarcinoma. Additionally, a Phase 1/2a trial for multi-specific T cell engager MP0533 is ongoing, with an update on its development path planned for H1 2026. The company also reported $93.1 million in cash and cash equivalents as of December 31, 2025, expected to fund operations until 2028.

Read more at GlobeNewswire: Molecular Partners Highlights Clinical Development Progress